Loading
CRISPR and Genetic Engineering · Journal article
Clinical Innovations in Health Research-hjm · August 12, 2026
A consensus or society position rather than new primary data.
This is a clinically oriented narrative review synthesizing the current status of CRISPR/Cas9-based therapies—including approved ex vivo hemoglobinopathy treatments and investigational in vivo programs—and outlining implementation barriers (off-target risk, immune safety, manufacturing, institutional readiness) relevant to clinical practice in Mexico and Latin America. The source positions CRISPR/Cas9 as a disease-specific platform requiring genotype confirmation, pre-treatment testing, structured follow-up, and multidisciplinary oversight rather than a universal intervention.
Narrative review of clinical translation. Patients with hematologic, hepatic, ophthalmologic, and cardiometabolic diseases amenable to CRISPR/Cas9 editing; clinical implementation context in Mexico and Latin America.. Intervention: CRISPR/Cas9-based therapies (ex vivo and in vivo editing programs). Mexico and Latin America (focus); global clinical-trial and regulatory evidence surveyed.
Ex vivo CRISPR/Cas9 editing for hemoglobinopathies has reached regulatory approval In vivo editing programs including NTLA-2001 and ocular CRISPR therapies remain in active clinical development Broad adoption in routine practice is constrained by off-target risk assessment, immune and long-term safety monitoring, manufacturing complexity, and need for multidisciplinary oversight
No quantitative efficacy or safety data reported; review does not provide effect sizes, event rates, or comparative outcomes Specific off-target risk rates, immune adverse events, or long-term follow-up durations not stated
Clinicians should recognize that CRISPR/Cas9 therapies are disease-specific tools with varying clinical maturity (approved for certain hemoglobinopathies; investigational for other indications), require careful pre-treatment testing and long-term monitoring, and demand institutional readiness including multidisciplinary oversight and structured follow-up protocols.
A clinical synthesis review summarizing current CRISPR/Cas9 therapies, regulatory status, and implementation requirements for a specific regional context; provides expert perspective rather than original experimental evidence.
As stated by the source record.
Clinicians should recognize that CRISPR/Cas9 therapies are disease-specific tools with varying clinical maturity (approved for certain hemoglobinopathies; investigational for other indications), require careful pre-treatment testing and long-term monitoring, and demand institutional readiness including multidisciplinary oversight and structured follow-up protocols.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
CRISPR/Cas9 has moved from a gene-editing platform used in experimental biology to a clinically relevant therapeutic technology with approved and investigational applications in hematologic, hepatic, ophthalmologic, and cardiometabolic diseases.The objective of this brief review is to provide a clinically oriented synthesis of current CRISPR/Cas9-based therapies, summarize key efficacy and safety considerations, and discuss the translational requirements for implementation in Mexico and Latin America.A focused literature review was conducted using clinical-trial registries and peer-reviewed reviews of clinical translation, with emphasis on therapies that have reached human studies, approved products, pre-treatment testing, follow-up needs, and the Mexican institutional context.The available evidence shows that ex vivo editing for hemoglobinopathies has already reached regulatory approval, while in vivo editing programs such as NTLA-2001 and ocular CRISPR therapies remain in active clinical development.However, broad adoption in routine practice remains constrained by off-target risk assessment, immune and long-term safety monitoring, manufacturing complexity, and the need for multidisciplinary oversight.In Mexico, recent developments at UNAM, the Instituto Nacional de Pediatría, and IPN suggest growing technical capacity, but clinical translation will require coordinated regulatory, bioethical, laboratory, and referral frameworks.CRISPR/Cas9 should therefore be understood not as a universal intervention, but as a disease-specific therapeutic platform whose safe implementation depends on genotype confirmation, pre-treatment testing, structured follow-up, and institutional readiness.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.